Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 19890371)

1.

Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.

Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D.

J Hum Hypertens. 2010 Apr;24(4):263-73. doi: 10.1038/jhh.2009.77. Epub 2009 Nov 5.

2.

Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.

Suzuki H, Kanno Y; Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group.

Hypertens Res. 2005 Apr;28(4):307-14. Erratum in: Hypertens Res. 2005 Jun;28(6):553.

PMID:
16138560
3.

Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.

Russell D, Stålhammar J, Bodegard J, Hasvold P, Thuresson M, Kjeldsen SE.

J Clin Hypertens (Greenwich). 2011 Mar;13(3):189-97. doi: 10.1111/j.1751-7176.2010.00410.x. Epub 2010 Dec 22.

PMID:
21366850
4.

An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.

Nakamura T, Kanno Y, Takenaka T, Suzuki H; Efficacy of Candesartan on Outcome in Saitama Trial Group.

Hypertens Res. 2005 May;28(5):415-23.

PMID:
16156505
5.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).

Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators.

Eur Heart J. 2009 May;30(10):1203-12. doi: 10.1093/eurheartj/ehp101. Epub 2009 Apr 4.

6.

Association of treatment with losartan vs candesartan and mortality among patients with heart failure.

Svanström H, Pasternak B, Hviid A.

JAMA. 2012 Apr 11;307(14):1506-12. doi: 10.1001/jama.2012.452.

PMID:
22496265
7.

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).

Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A; Study on Cognition and Prognosis in the Elderly study group.

J Am Coll Cardiol. 2004 Sep 15;44(6):1175-80.

8.

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.

Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA.

Int J Clin Pract. 2011 Mar;65(3):253-63. doi: 10.1111/j.1742-1241.2011.02633.x. Epub 2011 Feb 1. Review.

PMID:
21284790
9.
10.

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group.

J Hypertens. 2003 May;21(5):875-86.

PMID:
12714861
11.

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.

Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group.

Lancet. 2011 Feb 26;377(9767):741-50. doi: 10.1016/S0140-6736(11)60104-9.

PMID:
21316752
13.

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.

Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N, Mendiola A, Woo KS, Zhu JR, Mejia AD, Bunt T, Dumortier T, Smith RD.

Clin Ther. 2000 Oct;22(10):1186-203.

PMID:
11110230
14.

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.

Hasvold LP, Bodegård J, Thuresson M, Stålhammar J, Hammar N, Sundström J, Russell D, Kjeldsen SE.

J Hum Hypertens. 2014 Nov;28(11):663-9. doi: 10.1038/jhh.2014.43. Epub 2014 Jun 26.

15.

[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].

Cice G, Ferrara L, Tagliamonte E, Russo PE, Di Benedetto A, Iacono A.

Cardiologia. 1999 Dec;44(12):1071-6. Italian.

PMID:
10687258
16.

Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.

Shimamoto K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimada K, Tanaka H, Yoshiike N; J-HEALTH Study Committees.

Hypertens Res. 2008 Mar;31(3):469-78. doi: 10.1291/hypres.31.469.

PMID:
18497466
17.

[Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension].

Minami J, Ishimitsu T, Matsuoka H.

Nihon Jinzo Gakkai Shi. 2005;47(8):864-9. Japanese.

PMID:
16408430
18.

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.

Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group.

Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1195-201. doi: 10.1586/14779072.6.9.1195.

PMID:
18939907
20.

Health-care costs of losartan and candesartan in the primary treatment of hypertension.

Henriksson M, Russell D, Bodegard J, Kjeldsen S, Hasvold P, Stålhammar J, Levin LÅ.

J Hum Hypertens. 2011 Feb;25(2):130-6. doi: 10.1038/jhh.2010.36. Epub 2010 Apr 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk